Skip to main content
Wednesday 14 May 2025
twitter linkedin facebook rss
User account menu
  • Subscribe
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Commercialisation
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • White Papers
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
twitter linkedin facebook rss
Sign in

Deep Dive

Patients
USA election illustration

Deep Dive: Patients & Partnerships 2024

IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?

Patients
Pills and polls: What the 2024 election means for pharma

Pills and polls: What the 2024 election means for pharma

Patients
Empathy in action

Empathy in action: Designing person-focused healthcare mater...

Patients
Beyond clinical trials

Beyond clinical trials: Unleashing the power of patient-repo...

Patients
Advancing patient care

Advancing patient care through early and sustained collabora...

Patients
Preparing for the impact

Preparing for the impact of ESG policies on market access in...

  • Load more results

Editor's Picks

  1. Gilead ups its US investment plans by $11 billion
  2. UK trumpets a trade deal with India - but pharma isn't happy
  3. Vinay Prasad will replace Marks as CBER director
  4. Trump's budget would be "catastrophic" for federal R&D
  5. Pharma still in waiting mode after UK-US trade agreement
News
Call goes out for feedback on US health deregulation

Call goes out for feedback on US health deregulation

The Trump administration wants the public to join in the effort to cull redundant health regulations as part of its '10-for-one' deregulation policy.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Market Access
Bridging research and clinical guidelines
Sponsored

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Subscribe
 
 
rss facebook linkedin twitter
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company